Table 2

Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in intravenous immunoglobulin (IVIG) responding or non-responding patients with Kawasaki disease

Characteristic

IVIG responders (n = 36)

IVIG non-responders (n = 4)

P


Boys/girls, number

21/15

1/3

0.000

Age, months

22.4 (17.2)

30.5 (12.8)

0.000

Patients with CALs, number

7

2

0.000

Resistin, 102 ng/ml

Acute stage

0.35 (0.24)

0.64 (0.30)

0.032

Afebrile stage

0.21 (0.19) **

0.48 (0.35)

0.019

Subacute stage

0.12 (0.05) **

0.28 (0.19)

0.000

S100A12, 102 ng/ml

Acute stage

5.05 (3.22)

7.92 (2.61)

0.044

Afebrile stage

3.99 (3.49)

4.80 (4.26)

0.668

Subacute stage

2.35 (2.26)**

4.98 (4.75)

0.047

sRAGE, 102 pg/ml

Acute stage

3.07 (1.98)

2.37 (0.96)

0.493

Afebrile stage

6.00 (2.78)**

3.51 (2.64)

0.046

Subacute stage

7.19 (2.88)**

3.65 (3.27)

0.026


Results are mean (SD) unless stated otherwise. CALs, coronary artery lesions; **P < 0.01 compared with acute stage; P < 0.05 compared with afebrile stage.

Qi et al. Arthritis Research & Therapy 2012 14:R251   doi:10.1186/ar4094

Open Data